im curious with the way this is written. It describes the improvement in delivery with targetted cpp, yet it doesn't seem to state that we actually have a cpp that can do this yet, is that correct? I assume the aim as previously is to be able to inject with iv and then the cpp seeks out only the liver? Or is it injected directly into the liver?Interesting science to follow but would be nice to know exactly where we are actually at and exactly what we need to achieve to proceed to trials ie iv delivery and cell specific or direct injection to target tissue. I assume these will be the animal trials they have mentioned, are these intended to show cell specificity for liver as mentioned in this update. Is liver a target of our previously nominated internal priorities?
im curious with the way this is written. It describes the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $708.6M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |